No matches

2 search results for: jak inhibitors

Differential Effects of Dupilumab and <b>JAK</b> <b>Inhibitors</b> on CCL17 (TARC) in Patients With AD

Dermatology

Differential Effects of Dupilumab and JAK Inhibitors on CCL17 (TARC) in Patients With AD

4 min

expert video

In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Prof. Oscar Palomares compares the effects of biologics and JAK inhibitors on the biomarker CCL17 (TARC) in atopic dermatitis.

Dermatology

Impact of Advanced Systemic Therapies on Disease Control in AD

6 min

expert video

Dr. Simpson discusses impact of advanced systemic therapies in AD, and the link between inhibition of type 2 inflammation and reduced IgE levels.

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: BelgiumChange country/region